C07D 209/70 - [b]- or [c]-condensed containing carbocyclic rings other than six-membered
C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
The present invention relates to a novel pharmaceutical composition suitable for ophthalmic use comprising antibiotic and process to prepare the same. More particularly, the present invention relates to a pharmaceutical gel composition comprising aminoglycoside antibiotics such as plazomicin or its pharmaceutically acceptable salts thereof for the treatment of ocular infections.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
C07C 231/02 - Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medicinal preparations; Veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use; Food for babies; Dietary supplements for human beings; Dietary supplements for animals; Plasters, materials for dressings; Material for stopping teeth; Dental wax.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medicinal preparations; Veterinary preparations; Sanitary preparations for medical purposes; Dietetic food and substances adapted for medical or veterinary use; Food for babies; Dietary supplements for human beings; Dietary supplements for animals; Plasters, materials for dressings; Material for stopping teeth; Dental wax.
The present invention relates to stable, sterile, ready-to-use aqueous pharmaceutical formulation comprising nimodipine or its pharmaceutically acceptable salts, and pharmaceutically acceptable excipients. The present invention also relates to a stable, sterile, ready-to-use aqueous pharmaceutical formulation comprising nimodipine containing no more than about 0.41% w/v of nitroso impurity and no more than about 0.41% w/v of di-isopropyl impurity. The formulation is suitable for parenteral administration and is provided in a suitable container. The invention further relates to method of manufacture and sterilization of such formulations and using the formulation for prophylaxis and treatment of ischemic neurological deficits caused by cerebral vasospasm following subarachnoid hemorrhage of aneurysmal origin.
The present invention relates to a ready- to- use injectable formulation of potassium phosphate and a process for preparing the same. The invention particularly relates to a ready-to-use injectable formulation comprising monobasic potassium phosphate, dibasic potassium phosphate, water for injection and optionally containing a tonicity adjusting agent.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Disclosed herein are polymorphs of Resmetirom and polymorphs of the ammonium salt of Resmetirom, hydrates and solvates thereof and process for the preparation thereof.
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
11.
READY TO USE INJECTABLE COMPOSITIONS OF FLECAINIDE
The present invention relates to a ready to use injectable composition comprising flecainide or its pharmaceutically acceptable salts thereof in a chloride containing pharmaceutically acceptable vehicle. The invention also covers process of preparing the said composition and its use in the treatment of paroxysmal supraventricular tachycardias and paroxysmal atrial fibrillation/flutter.
The present invention discloses injectable pharmaceutical composition comprising flecainide or its pharmaceutically acceptable salts thereof. The invention particularly discloses a ready-to-dilute injectable composition comprising flecainide or its pharmaceutically acceptable salts thereof and atleast one tonicity adjusting agent.
The present invention relates to new crystalline forms of Daprodustat. In particular, new crystalline polymorphic forms/co-crystals, designated Form C1, C2, C3, C4, and C5 of Daprodustat are provided. These are characterized by PXRD and TGA. Processes for preparing the new crystalline polymorphic forms/co-crystals and their use in pharmaceutical compositions are also provided.
The present invention relates to the combination of meropenem and one or more antibiotic resistance breakers, pharmaceutical compositions containing the same, and methods for treating bacterial infections that include administering the same. Particularly, it relates to a pharmaceutical composition comprising (a) meropenem, (b) avibactam, and (c) EDTA.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present invention relates to injectable pharmaceutical composition comprising metolazone. The invention particularly relates to a ready-to-dilute composition comprising metolazone and pharmaceutically acceptable excipients, process of preparing the composition and its use in the treatment of salt and water retention.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
16.
A SAFE PHARMACEUTICAL COMPOSITION OF HYDROCORTISONE
The present invention discloses an aqueous pharmaceutical composition of hydrocortisone that is free of any adverse and side effects due to the inactive ingredients used in the formulation. The present invention relates to ready to use safe stable aqueous pharmaceutical composition comprising hydrocortisone sodium phosphate comprising pH adjuster, antioxidant, buffering agent and vehicle. The present invention also discloses stability of an aqueous pharmaceutical composition comprising hydrocortisone sodium phosphate with different headspace.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Provided is a composition of inhalation either by oral or nasal route comprising ensifentrine or pharmaceutically acceptable salt or ester thereof, pharmaceutically acceptable propellant and a pharmaceutically acceptable excipient. More preferably, provided is a composition of inhalation either by oral or nasal route comprising ensifentrine or pharmaceutically acceptable salt or ester thereof, pharmaceutically acceptable propellant having GWP less than 200 and a pharmaceutically acceptable excipient.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61P 11/00 - Drugs for disorders of the respiratory system
A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
The present invention relates to solid state forms of Gonadotropin-Releasing Hormone Receptor (GnRH) antagonist of Formula (I) and a pharmaceutically acceptable salt thereof, namely 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy pyridazin-3-yl-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea, and its pharmaceutically acceptable salts thereof, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
A stable, sterile, ready-to-use aqueous pharmaceutical formulation comprising flucytosine or its pharmaceutically acceptable salts and pharmaceutically acceptable excipients in glass container for intravenous and intraperitoneal administration. The formulation is manufactured by aseptic fill finish and filled in suitable presterilized glass container. The formulation is suitable for treating systemic yeast and fungal infections.
The present invention relates to a method for in-vitro assessment of drug formulations using A549 cells. Particularly, the present invention provides a method for evaluating deposition and permeability of an active agent of an inhalation formulation, particularly by evaluating BDP and its metabolite 17-BMP using A549 cells. The method of the present invention is simple, effective, and non-invasive.
Described herein are compositions of pMDIs for administration of medications, wherein the composition comprises a green propellant, an active ingredient, and a pharmaceutical acceptable excipient. The invention further describes a process for preparation of said green-propellant based composition.
The present invention relates to sterile ready to use aqueous pharmaceutical formulation comprising flucytosine and pharmaceutically acceptable excipients wherein the pH of formulation is maintained between 6.0 to 8.0. The invention further relates to the method of manufacture and sterilization of such formulations and using the formulation for treating systemic yeast and fungal infections.
The present invention relates to an aqueous injectable composition comprising celecoxib or its pharmaceutically acceptable salts thereof. The invention particularly relates to a ready-to-dilute composition comprising celecoxib or its pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients, process of preparing the composition and its use in the treatment of acute pain, especially post- operative pain.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The present invention relates to solid state forms of Ensifentrine and methods for preparation, use and isolation of such compounds and novel process for the preparation of Ensifentrine. The present invention further relates to an improved, cost effective and industrially viable process for preparation of Ensifentrine.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
The present invention relates to stable injectable pharmaceutical composition comprising posaconazole or its pharmaceutically acceptable salts thereof. The invention particularly relates to a ready-to-dilute composition comprising posaconazole or its pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients, process of preparing the composition and its use in the treatment of fungal infections caused by Aspergillus and Candida species.
The present invention discloses to a long acting injectable composition comprising cariprazine or its pharmaceutically acceptable salts thereof and process to prepare the same. The present invention also discloses to use of the long acting injectable composition comprising cariprazine or its pharmaceutically acceptable salts thereof in the treatment of psychotic disorders.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a novel pharmaceutical composition suitable for ophthalmic use comprising antibiotic such as plazomicin or its pharmaceutically acceptable salts and a process to prepare the same for use in the treatment of ocular infections.
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A stable, sterile, ready-to-use aqueous pharmaceutical formulation comprising flucytosine or its pharmaceutically acceptable salts and pharmaceutically acceptable excipients in flexible plastic container for intravenous and intraperitoneal administration. The formulation is manufactured by aseptic fill finish and filled in suitable presterilized infusion bag. The formulation is suitable for treating systemic yeast and fungal infections.
The present disclosure relates to novel solid state forms of Tafamidis of Formula (I), and process for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions. Such compositions may be used for the treatment of transthyretin-related hereditary amyloidosis, neurodegenerative diseases, amyloidosis, neuropathic pain, amyloid fibril formation and cardiomyopathy related diseases.
The present invention relates to a topical composition comprising pirfenidone and process to prepare the same. The present invention also relates to use of the topical composition comprising pirfenidone in the treatment of skin disorders of the dermis of fibrous or inflammatory origin.
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
The present invention relates to an improved process for the preparation of (((1-(6-amino-9H- purin-9-yl)propan-2-yloxy)methyl)(phenoxy)phosphoryloxy)methyl pivalate Compound (1) or its pharmaceutically acceptable salts thereof. The compound is useful as nucleotide reverse transcriptase inhibitor in therapy for diseases which respond to inhibition of protein kinase activity in humans in need thereof.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
Disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant. Particularly, disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant HFA-152a and/or HFO-1234ze(E). Also disclosed processes of preparing such compositions.
Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of desipramine or a salt thereof. The compositions include an effective amount of desipramine or a salt thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
The present invention relates to methods of treatment of infections caused by coronaviridae virus (including COV-ID-19) using ((((((R)-1-(6-amino-9h-purin-9-yl) propan-2-yl) oxy) methyl) (phenoxy) phosphoryl)oxy)methyl pivalate, its derivatives or metabolites thereof. The methods of the present invention can be used in patients with infections caused by coronaviridae virus (including COVID-19) administering ((((((R)-1-(6-amino-9h-purin-9-yl) propan-2-yl) oxy) methyl) (phenoxy) phosphoryl)oxy)methyl pivalate, its derivatives or metabolites in combination with one or more anti-viral drugs.
This invention relates to novel pharmaceutical formulations of Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib. This invention also relates to methods of using the Ibrutinib pharmaceutical formulations, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, cancers, including lymphoma, and inflammatory diseases or conditions.
Long term storage stable injectable phytonadione containing liquid pharmaceutical formulations are disclosed. The compositions can include phytonadione or pharmaceutically acceptable salts thereof; an antioxidant; buffer, pH adjusting agent and a pharmaceutically acceptable fluid. The methods of preparing the formulation as well as methods of treatment of phytonadione deficiency diseases using the same are also disclosed.
Stable ready-to-use extended release injectable pharmaceutical formulation comprising Aripiprazole are provided. The invention further relates to the method for preparing the above formulation, and a method for treating schizophrenia and related disorders employing the above formulation.
: The present invention relates to fixed dose pharmaceutical formulations of nirmatrelvir, ritonavir and pharmaceutically acceptable excipients, their use and process for preparing the said formulations.
: The present invention relates to stable injectable pharmaceutical composition comprising azole antifungal agent. The invention particularly relates to a ready-to- use composition comprising posaconazole or its pharmaceutically acceptable salts, derivatives thereof and pharmaceutically acceptable excipients, process of preparing the composition and its use in the treatment of fungal infections caused by Aspergillus and Candida species.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products, preparations for medical and veterinary use; Pharmaceutical compounds; Pharmaceutical products for veterinary use; Hygienic and sanitary products for medical use; Personal hygiene products other than toiletries; Dietary foods and substances for medical or veterinary use, baby food; Dietary fibers for use as food additive or nutritional dietary supplements; Food supplements for humans and animals; Dietary fiber supplements; Food supplements of animal and vegetable origin; medicated food supplements for animals; plasters, surgical plasters, plasters for medical use, material for dressings; material for dental fillings and dental impressions; waxes for dental impressions; orthodontic alginates for dental impressions; disinfectants; cleaning wipes impregnated with disinfectant for hygienic use; disinfectants for veterinary use; disinfectant gels and soaps; products for eliminating parasites; fungicides, fungicides for domestic use, fungicides for medical use; herbicides, chemical products for forestry, herbicides for domestic use.
43.
METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORME THEREOF
The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical compositions comprising the salts and solid forms and to use of said compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
A pharmaceutical compositions provided for the treatment of proliferative disorders. The composition comprises a therapeutically effective amount of ibrutinib and a therapeutically effective amount of at least one alkaloid or derivative thereof. Methods and kits are also provided.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
The present invention relates to solid state forms of Gonadotropin-Releasing Hormone Receptor (GnRH) antagonist of Formula (I) and a pharmaceutically acceptable salt thereof, namely 1-(4-(l-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy pyridazin-3-yl -2,4-dioxo-l,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea, and its pharmaceutically acceptable salts thereof, methods of their preparation, pharmaceutical compositions thereof and methods of their use.
The present invention relates to the solid forms of Nilotinib D-Malate and Nilotinib D-Tartrate, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of Quetiapine or derivative thereof. The compositions include an effective amount of Quetiapine or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Surgical, medical, dental, and veterinary apparatus and instruments namely respiratory devices.
The present disclosure relates to co-crystals, salts and crystalline forms of Niraparib of Formula (I). More particularly, the present invention relates to novel polymorphic forms and synergistic pharmaceutical co-crystals comprising Niraparib and to processes of preparation thereof. The invention further relates to pharmaceutical compositions comprising novel polymorphic forms and synergistic co-crystals and at least one pharmaceutically acceptable excipient. The invention further provides novel crystalline forms of the novel pharmaceutical co-crystals.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
C07D 401/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
53.
Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
The present invention relates to pharmaceutical composition for intranasal or pulmonary delivery, wherein the composition comprises an artemisinin derivative and optionally one or more pharmaceutically acceptable excipients. The pharmaceutical composition may be for intranasal delivery, may be in the form of a nasal spray, a solution, a suspension, nasal drops, an insufflation powder or a nasal powder, and may be suitable for delivery using a nebulizer, insufflator, powder sprayer or powder inhaler. Alternatively, the pharmaceutical composition may be for pulmonary delivery, may be in the form of an aerosol composition or a powder, and may be suitable for delivery using a metered dose inhaler (MDI) or a dry powder inhaler (DPI). The present invention also relates to processes for preparing such compositions and to the use of such compositions for the treatment of malaria.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The present invention discloses to a long acting injectable composition comprising cariprazine or its pharmaceutically acceptable salts thereof and process to prepare the same. The present invention also discloses to use of the long acting injectable composition comprising cariprazine or its pharmaceutically acceptable salts thereof in the treatment of psychotic disorders.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Surgical, medical, dental, and veterinary apparatus and instruments; artificial limbs, eyes, and teeth; orthopaedic articles; suture materials; therapeutic and assistive devices adapted for persons with disabilities; massage apparatus; apparatus, devices and articles for nursing infants; sexual activity apparatus, devices and articles.
56.
SOLID STATE FORMS OF 2-(3,5-DICHLOROPHENYL)-1,3-BENZOXAZOLE-6-CARBOXYLIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND POLYMORPHS THEREOF
The present disclosure relates to novel solid state forms of Tafamidis of Formula (I), and process for preparation thereof. The invention is also directed to pharmaceutical compositions containing at least one solid form and to the therapeutic or prophylactic use of such solid forms and compositions. Such compositions may be used for the treatment of transthyretin-related hereditary amyloidosis, neurodegenerative diseases, amyloidosis, neuropathic pain, amyloid fibril formation and cardiomyopathy related diseases.
C07D 473/04 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
57.
INHALATION COMPOSITION OF NITAZOXANIDE OR ITS DERIVATIVES FOR USE IN CORONAVIRUS DISEASE
The present invention relates to an inhalation composition comprising nitazoxanide or its derivatives to a patient (e.g., a human). The present invention further relates to method of treating Coronavirus disease by administering nitazoxanide or derivatives thereof. The present invention also relates to use of the inhalation composition comprising nitazoxanide or its derivatives for the treatment of Coronavirus disease.
A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
The present invention relates to a topical composition comprising pirfenidone and process to prepare the same. The present invention also relates to use of the topical composition comprising pirfenidone in the treatment of skin disorders of the dermis of fibrous or inflammatory origin.
The present invention relates to method of increasing the bioavailability/bio-efficacy of tizanidine by co-administering with resveratrol and bioenhancer. The formulation comprising tizanidine, resvetarol and bioenhancer are also provided which can be used for treatment of muscle spasticity.
The present invention relates to an inhalation composition comprising artemisinin or its derivatives to a patient (e.g., a human). The present invention further relates to method of treating Coronavirus disease by administering artemisinin or derivatives thereof. The present invention also relates to use of the inhalation composition comprising artemisinin or its derivatives for the treatment of Coronavirus disease.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
The present invention relates to methods of treatment of infections caused by coronaviridae virus (including COVID-19) using ((((((R)-1-(6-amino-9h-purin-9-yl) propan-2-yl) oxy) methyl) (phenoxy) phosphoryl)oxy)methyl pivalate, its derivatives or metabolites thereof. The methods of the present invention can be used in patients with infections caused by coronaviridae virus (including COVID-19) administering ((((((R)-1-(6-amino-9h-purin-9-yl) propan-2-yl) oxy) methyl) (phenoxy) phosphoryl)oxy)methyl pivalate, its derivatives or metabolites in combination with one or more anti-viral drugs.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Novel crystalline forms of Bictegravir sodium, pharmaceutical compositions containing said crystalline forms and the use of said crystalline forms in the treatment of HIV infection are disclosed. The present invention is further directed to the processes for the preparation of the novel crystalline forms.
The invention is directed to stable formulations of nucleotide analogue prodrug, in particular remdesivir in the form of ready-to-use (RTU) and ready-to-dilute (RTD) formulations which are free of cyclodextrins.
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
The invention relates to a pharmaceutical composition administered in a form of injection comprising fixed dose of two or more active ingredients namely Cabotegravir and Rilpivirine and optionally other active ingredients, a process for preparing such pharmaceutical composition. Use of such fixed dose pharmaceutical composition for the prevention, treatment and prophylaxis of AIDS are also described herein.
A pharmaceutical composition is provided comprising combination of antiretroviral drugs optionally in combination of pharmacokinetic boosters. The formulation is used for the treatment of diseases caused by retroviruses. The process of preparation of the formulation is also provided.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
66.
SOLID FORMS OF SUBSTITUTED POLYCYCLIC PYRIDONE COMPOUNDS AND PRODRUGS THEROF AND PROCESS OF PREPARATION THEREOF
Novel solid forms of substituted polycyclic pyridine compounds and prodrugs thereof, processes for their preparation, pharmaceutical compositions comprising the new solid forms, and use of the new solid forms for treating influenza A or B including strains resistant to current antiviral agents, are disclosed. These solid forms can be advantageously used to increase the chemical and polymorphic stability of substituted polycyclic pyridine compounds and prodrugs thereof.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
Long term storage stable injectable phytonadione containing liquid pharmaceutical formulations are disclosed. The compositions can include phytonadione or pharmaceutically acceptable salts thereof; an antioxidant; buffer, pH adjusting agent and a pharmaceutically acceptable fluid. The methods of preparing the formulation as well as methods of treatment of phytonadione deficiency diseases using the same are also disclosed.
An apparatus (100), a system (200), and a method (500) for simulating deposition of an inhaled drug on lungs of an individual are disclosed. The apparatus (100) includes a mouth-throat model (102), an inhalation device (104), and a breath simulator (106) connected to the mouth-throat model (102) for dispersing drug and respiration flow respectively in the mouth-throat model (102). The apparatus (100) also includes a controlling unit (108) in communication with the breath simulator (106) and the inhalation device (104) to detect the dispersion of the respiration flow and actuate the inhalation device (104) to disperse the drug. The respiration flow and the drug are uniformly mixed while passing through a mixing unit (110) formed downstream to the mouth-throat model (102) and the breath simulator (106). The mixture is then received by a lung cast model (112) formed downstream to the mixing unit (110) to accommodate deposition of the drug.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Surgical, medical, dental and veterinary apparatus and instruments; artificial limbs, eyes and teeth; orthopaedic articles; suture materials; therapeutic and assistive devices adapted for persons with disabilities; massage apparatus; apparatus, devices and articles for nursing infants; sexual activity apparatus, devices and articles.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Surgical, medical, dental and veterinary apparatus and instruments; artificial limbs, eyes and teeth; orthopaedic articles; suture materials; therapeutic and assistive devices adapted for persons with disabilities; massage apparatus; apparatus, devices and articles for nursing infants; sexual activity apparatus, devices and articles.
Methods of treating bladder cancer using adapalene are disclosed herein. Adapalene can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.
The present invention discloses novel crystalline polymorphic forms of Acalabrutinib, methods of preparation, pharmaceutical compositions and methods of therapeutic treatment involving polymorphic forms thereof.
The present invention relates to the formulation of midazolam. In particular, the invention provides new midazolam formulation for intranasal administration. These formulations contain midazolam in a high concentration from about 1% to about 10% w/w of the formulation and process of preparation thereof.
A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
75.
METHODS FOR THE PREPARATION OF SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATORS AND SOLID FORMS THEREOF
The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical compositions comprising the salts and solid forms and to use of said compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 317/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for human beings and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. Surgical, medical, dental and veterinary apparatus and instruments; artificial limbs, eyes and teeth; orthopaedic articles; suture materials; therapeutic and assistive devices adapted for persons with disabilities; massage apparatus; apparatus, devices and articles for nursing infants; sexual activity apparatus, devices and articles.
Soft gelatin capsules comprising a suspension composition of nintedanib or a pharmaceutically acceptable salt thereof in medium chain triglycerides and carrier system, wherein the carrier system comprises solubilizers, phospholipids, thickeners and mixtures thereof.
The present subject matter refers a blister-strip based dispenser (100) comprising a lever arm rotatable on receiving a user-actuation. A chassis (106, 108) is provided for supporting placement of at least one blister-strip (104) in the form of the coil. The blister-strip (104) comprises medicament-pockets at at-least one side of the blister-strip (104). A plurality of interconnected-rollers (110, 114, 116) comprises at-least one roller linked to the lever-arm and rotatable by the lever arm. The plurality of interconnected rollers (110, 114, 116) are configured for anchoring the blister-strip (104) from one end for enabling the placement in a coil-form and unwinding of the blister strip (104) from the coil-form, guiding at least two split-portions of the blister-strip (104), anchoring an end of each of said at-least two portions of the blister-strip (104) for winding the at-least two portions separately, and anchoring an end of a lid-foil peeled off the at least two portions for winding the lid-foil.
A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
Stable ready-to-use extended release injectable pharmaceutical formulation comprising Aripiprazole are provided. The invention further relates to the method for preparing the above formulation, and a method for treating schizophrenia and related disorders employing the above formulation.
Disclosed is a method for treating of cancer, specifically pancreatic cancer by administering a selective estrogen receptor modulator (SERM), e.g., levormeloxifene, alone or in combination with one or more additional cancer therapies.
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61P 35/04 - Antineoplastic agents specific for metastasis
83.
NOVEL SALTS AND/OR CO-CRYSTALS OF TENOFOVIR ALAFENAMIDE
The present invention relates to novel salts and/or co-crystals of tenofovir alafenamide with an acid selected from D-malic acid and adipic acid. Another aspect of the present invention relates to novel crystalline forms of the novel salts and/or co-crystals tenofovir alafenamide, process for preparation, the pharmaceutical formulations and therapeutic uses thereof for the treatment of diseases or symptoms of HIV infection and viral hepatitis B.
C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
The present invention relates to the solid forms of Nilotinib D-Malate and Nilotinib D-Tartrate, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention relates to a long term storage stable multi-dose ready-to use or ready-to dilute pharmaceutical liquid formulation comprising pemetrexed or a pharmaceutically acceptable salt thereof, an antioxidant, a preservative, a buffering agent, and a pharmaceutically acceptable fluid. The invention also relates to a process of preparing the formulation, a kit and a method of treatment of patients having lung cancer by administering the pharmaceutical formulation to a subject in need thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A pharmaceutical long acting depot composition is provided as an aid to smoking cessation treatment. The formulation comprises a therapeutically effective amount of varenicline or its pharmaceutically acceptable derivative and pharmaceutically acceptable excipients. The process of preparation of the formulation is also provided.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A pharmaceutical formulation is provided comprising combination of anti-tuberculosis drug drugs optionally in combination of bioenhancers. The formulation is used for the treatment of diseases caused by mycobacterium tuberculosis. The process of preparation of the formulation is also provided.
The invention provides certain cocrystals of Olaparib and provides novel polymorphic forms of certain cocrystals of Olaparib. In particular, cocrystals of Olaparib with fumaric acid and 3,5-dihydroxybenzoic acid are described. The invention further provides methods of preparation and characterization of such cocrystals of Olaparib. In addition, the present invention relates to pharmaceutical composition containing the cocrystals of Olaparib and a method of treating disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said composition.
An adherence-monitoring and tracking device captures usage of a metered dose inhaler (MDI). The device includes an enclosure for enclosing a metered dose inhaler (MDI), and an electro-mechanical system forming a part of enclosure to sense and log the operation of the MDI. The electro-mechanical system includes at-least one transducer to capture one or more parameters pertaining to an operation of the MDI by the user. A microcontroller processes the captured parameters, and an output-unit renders data pertaining to operation of the MDI.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
An oral or injectable pharmaceutical composition is provided for treating diseases caused by retroviruses or hepatitis B viruses. The composition comprises a therapeutically effective amount of at least one anti-retroviral drug and a therapeutically effective amount of at least one pharmacokinetic booster or enhancer or derivative thereof. Methods and kits are also provided.
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 9/24 - Layered or laminated unitary dosage forms
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
An apparatus (100), a system (200), and a method (500) for simulating deposition of an inhaled drug on lungs of an individual are disclosed. The apparatus (100) includes a mouth-throat model (102), an inhalation device (104), and a breath simulator (106) connected to the mouth-throat model (102) for dispersing drug and respiration flow respectively in the mouth-throat model (102). The apparatus (100) also includes a controlling unit (108) in communication with the breath simulator (106) and the inhalation device (104) to detect the dispersion of the respiration flow and actuate the inhalation device (104) to disperse the drug. The respiration flow and the drug are uniformly mixed while passing through a mixing unit (110) formed downstream to the mouth-throat model (102) and the breath simulator (106). The mixture is then received by a lung cast model (112) formed downstream to the mixing unit (110) to accommodate deposition of the drug.
The present invention relates to method of increasing the bioavailability / bio-efficacy of tizanidine by co-administering with resveratrol and bioenhancer. The formulation comprising tizanidine, resvetarol and bioenhancer are also provided which can be used for treatment of muscle spasticity.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medicinal preparations for the treatment, alleviation and prevention of genitourinary diseases and disorders, namely, urological diseases, urological disorders, urinary incontinence
Novel crystalline forms of Bictegravir sodium, pharmaceutical compositions containing said crystalline forms and the use of said crystalline forms in the treatment of HIV infection are disclosed. The present invention is further directed to the processes for the preparation of the novel crystalline forms.
A61K 31/537 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
Disclosed herein are methods for treating cancer in a subject in need thereof by administering an agent or pharmaceutically acceptable derivative thereof, optionally with another agent, induces prostate apoptosis response-4 (Par-4) production by non-cancerous normal cells, to promote apoptosis in cancer cells.
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/35 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61P 35/04 - Antineoplastic agents specific for metastasis
96.
Flow sensing arrangement for spirometer and method thereof
A flow-sensing arrangement within a spirometer. The arrangement includes a tubular-member for allowing an air-passage along a longitudinal-axis thereof. At-least two disc-shaped air-resistive elements are removably-arranged within the tubular member to resist the air-flow. Each of the resistive-elements include perforations for allowing the air-passage through the resistive-element. At-least two ports extend radially outward through a wall of the tubular member, such that each of the two ports are located within the tubular-member near the resistive-elements to cause determination of at least a pressure-difference there-between.
The present invention relates to the formulation of midazolam. In particular, the invention provides new midazolam formulation for intranasal administration. These formulations contain midazolam in a high concentration from about 1% to about10% w/w of the formulation and process of preparation thereof.
The present invention pertains to a high drug load tablet comprising pirfenidone as active ingredient in an amount from about 30% to 80% in weight of the active moiety based on the total weight of the tablet.
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceuticals, medical and veterinary preparations; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use, food for babies; dietary supplements for humans and animals; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
The present invention relates to a long term storage stable multi-dose ready-to use or ready-to dilute pharmaceutical liquid formulation comprising pemetrexed or a pharmaceutically acceptable salt thereof, an antioxidant, a preservative, a buffering agent, and a pharmaceutically acceptable fluid. The invention also relates to a process of preparing the formulation, a kit and a method of treatment of patients having lung cancer by administering the pharmaceutical formulation to a subject in need thereof.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
